Fig. 3
From: Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives
Intestinal effects of SGLT-1 inhibition by sotagliflozin. By inhibiting SGLT-1 sotagliflozin reduces PPG and improves glycemic control. Possible mechanisms are: (1) delayed glucose absorption in the distal small intestine; (2) consequent increased GLP-1 secretion by L cells, mostly located in the cecum, and (3) delayed glucose in the colon where it could promote changes in microbiota and increase production of SCFAs; the latter seems to independently increase GLP-1 secretion. G glucose, GIP gastric inhibitory peptide, GLP glucagon like peptide, SCFAs short chain fatty acids